The Muscle Spasm drugs in development market research report provides comprehensive information on the therapeutics under development for Muscle Spasm, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Muscle Spasm. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Muscle Spasm and features dormant and discontinued products.
GlobalData tracks seven drugs in development for Muscle Spasm by seven companies/universities/institutes. The top development phase for Muscle Spasm is preclinical with two drugs in that stage. The Muscle Spasm pipeline has seven drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Muscle Spasm pipeline products market are: Daewon Pharmaceutical, Viatris and Merz Pharma GmbH & Co.
The key targets in the Muscle Spasm pipeline products market include Synaptosomal Associated Protein 25, Type 1 Angiotensin II Receptor, and Voltage Dependent Calcium Channel.
The key mechanisms of action in the Muscle Spasm pipeline product include Synaptosomal Associated Protein 25 Inhibitor with two drugs in Preclinical. The Muscle Spasm pipeline products include six routes of administration with the top ROA being Subcutaneous and four key molecule types in the Muscle Spasm pipeline products market including Protein, and Small Molecule.
Muscle Spasm overview
A muscle spasm, also known as a charley horse or muscle cramp, refers to the involuntary and forceful contraction of a muscle, most commonly in the thighs, calves, feet, hands, and arms. They can also occur in the abdomen or along the rib cage. Muscle spasms are typically harmless, but they may result in an inability to use the affected muscle for a short period of time.
For a complete picture of Muscle Spasm’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
